The longevity of multiple myeloma patients increased sharply since the late 1990s. This increase coincided with the introduction of several important innovations in chemotherapy for myeloma. In this study, we aim to quantify the impact of recent chemotherapy innovation on the longevity of myeloma patients using both time-series US data and longitudinal data on 38 countries.
Introduction
Myeloma is a type of bone marrow cancer, where plasma cells found in the bone marrow divide uncontrollably and form tumors that can destroy bones and damage the kidneys (Harrison, 2013) . The incidence varies globally from 1 per 100,000 people in China, to about 4 per 100,000 in most developed countries. Thus it is a rare disease, but it is the second most frequent malignancy of the blood in the US, where about 20,000 new cases occur every year. Median age at diagnosis is reported to lie between 61 and 70 years of age, and only 2% of patients are younger than 40 years (Cook, 2008; Raab et al., 2009) . About 90% of myeloma patients have multiple myeloma (MM), which is myeloma that affects several different parts of the body. Fig. 1 shows the age-adjusted multiple myeloma mortality rate per 100,000 inhabitants for the US population for the period 1975e2009.
After rising for about 20 years, the US MM mortality rate has fallen steadily since 1997. In this paper, we investigate the extent to which the recent decline in myeloma mortality was caused by recent innovation in chemotherapy, and whether a similar impact can also be observed in other countries.
First, we will investigate this impact using annual US time-series data during the period 1975e2009. We believe that the sharp discontinuity in the number of available chemotherapy regimens enables us to identify this impact. Second, we will investigate this impact using longitudinal country-level data on 38 countries during the period 2002e2012. In this case, identification is enabled by the fact that some chemotherapy regimens became available later in some countries than in others, or did not become available in some countries by the end of 2010.
In both approaches, the treatment variable is the (current or lagged) number of chemotherapy regimens that could have been used to treat myeloma patients. This is not an ideal treatment measure: we would prefer to have data on the number of patients actually treated with each regimen. Unfortunately, data on the number of myeloma patients treated, by chemotherapy regimen and year (and country), are not available. However, there is likely to be a significant correlation between the number of available treatments and the distribution of actual treatments. If a treatment is not available, the number of patients receiving that treatment is certainly zero. Lichtenberg (2014) showed that when the number of drugs in a drug class increases, the mean vintage (FDA approval year) of drugs consumed increases. Two reliable sources indicate that, between 1977 and 1997, there were no innovations in chemotherapy for myeloma patients and treatment options were therefore limited, but that there have been numerous innovations since 1997. The first source is the National Cancer Institute (NCI) Thesaurus database, which identifies chemotherapy regimens currently used to treat myeloma (see Appendix 1). Chemotherapy is defined as the treatment of cancer using specific chemical agents or drugs that are selectively destructive to malignant cells and tissues. The NCI Thesaurus (NCIt) also identifies the substances included in each regimen. For example, one of the regimens used to treat -myeloma is the "lenalidomide-dexamethasone regimen," which has three components: dexamethasone, bortezomib, and lenalidomide (NCIt, 2012) . These three drugs were approved by the Food and Drug Administration (FDA) in 1958, 2003, and 2005, respectively (Drugs@FDA, 2012).
Therefore, 2005 is the first year in which a myeloma patient in the US could have been treated with the lenalidomidedexamethasone regimen. Table 1 shows the regimens used to treat plasma cell myeloma, (as defined in the NCI Thesaurus and OncologySTAT) the drugs included in each regimen, the FDA approval year of those drugs, and the "regimen year": the FDA approval year of the most recently approved drug included in the regimen.
Six of the twelve regimens currently used to treat plasma cell myeloma could have been used by the year 1977. No new regimens were added during the next 20 years. Due to the approval of three new drugs (thalidomide, bortezomib, and lenalidomide), the number of available regimens doubled (from six to twelve) between 1997 and 2005 (Fig. 2) . Before 1997, treatment options were quite limited, particularly for patients who relapsed. The only real treatment option available besides supportive treatments was stem cell transplantation, which was introduced in the 1980s. However, patients must be fairly young and healthy to withstand the sideeffects of transplantation. Many myeloma patients therefore do not qualify for transplantation. Ramesh and Maike (2013) reports that only about 5% of myeloma patients received stem-cell transplantations in 1994. Thalidomide was the first-in-class immunomodulatory agent with an indication for multiple myeloma (MM). Thalidomide and lenalidomide target both myeloma cells and the bone marrow microenvironment (Raab et al., 2009) , whereas bortezomib is a chemotherapeutic agent that induces cancer cell death by inhibiting the proteasome enzyme complex involved in cell cycle control and growth (Harrison, 2013) . These agents target the immune system in such a way that patients suffer minimum damage, and normal function of the immune system remains intact (V. Kumar and Chhibber, 2011) .
The second source is The Elsevier Guide to Oncology Drugs and Regimens (2012 edition) (also known as OncologySTAT) (Elsevier, 2012) . OncologySTAT provides a comprehensive list of more than 290 commonly used single-agent and combination regimens used in the treatment of 26 cancer types. The regimens listed are those most widely used and are in accordance with guideline recommendations of the National Comprehensive Cancer Network, American Society of Clinical Oncology, and National Cancer Institute. They were selected by oncologists at major US cancer centers, including members of the OncologySTAT Advisory Board. (Appendix 2 shows OncologySTAT's website with the list of chemotherapy regimens used to treat myeloma.)
The NCIt and OncologySTAT lists of myeloma chemotherapy regimens differ in some respects. The NCIt list includes twice as many "old" (pre-1998) regimens as the OncologySTAT list: six as opposed to three. OncologySTAT also distinguishes between regimens designated by specialists as preferred for use in clinical practice and regimens that are not preferred. Preferred status may be interpreted as first-line therapies for certain groups of patients. As shown in Table 1 , half of the OncologySTAT regimens are preferred regimens, and all of these are "new" (post-1997) regimens.
Although there are some discrepancies, both sources indicate that there were no innovations in chemotherapy for myeloma patients during the period 1977e1997, but that there have been numerous innovations since 1997. This is illustrated in Fig. 1, which shows annual data on the number of NCIt regimens, OncologySTAT regimens, and preferred OncologySTAT regimens that could have been used to treat myeloma patients in the US during the period 1977e2012.
In Section 2 we will review the related literature. In Section 3 we will analyze the impact of chemotherapy innovation on the longevity of myeloma patients using annual US time-series data 
